398,782 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC purchased a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 398,782 shares of the company’s stock, valued at approximately $7,162,000. Parkman Healthcare Partners LLC owned approximately 0.36% of Amylyx Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter worth about $158,534,000. Adage Capital Partners GP L.L.C. grew its stake in shares of Amylyx Pharmaceuticals by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock valued at $56,408,000 after buying an additional 3,102,395 shares in the last quarter. Millennium Management LLC grew its stake in shares of Amylyx Pharmaceuticals by 418.6% in the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock valued at $10,910,000 after buying an additional 2,487,617 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Amylyx Pharmaceuticals by 76.1% during the 4th quarter. Janus Henderson Group PLC now owns 4,465,872 shares of the company’s stock valued at $53,992,000 after buying an additional 1,929,639 shares during the period. Finally, Paradigm Biocapital Advisors LP purchased a new stake in shares of Amylyx Pharmaceuticals during the 3rd quarter valued at about $25,821,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the transaction, the insider directly owned 194,090 shares in the company, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 10.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AMLX. HC Wainwright upped their price target on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Guggenheim lifted their price objective on shares of Amylyx Pharmaceuticals from $40.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. Citigroup boosted their target price on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Wall Street Zen downgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $36.25.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ AMLX opened at $38.15 on Tuesday. Amylyx Pharmaceuticals, Inc. has a 1 year low of $8.47 and a 1 year high of $41.14. The stock’s 50-day simple moving average is $20.83 and its 200-day simple moving average is $16.87. The firm has a market cap of $4.25 billion, a price-to-earnings ratio of -26.68 and a beta of -0.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). As a group, research analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current year.

Amylyx Pharmaceuticals Profile